Marta Capelán

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet et al. · Nature Communications · 2022 · 113 citations · Full text

The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer

Marta Capelán, Nicolò Matteo Luca Battisti, Anne McLoughlin et al. · British Journal of Cancer · 2017 · 47 citations · Full text

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Saeed Rafii, Desamparados Roda, Elena Geuna et al. · Clinical Cancer Research · 2015 · 35 citations · Full text

Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer

Hazel Lote, Adam Sharp, Stefania Redana et al. · Clinical Oncology · 2016 · 31 citations

Breast Oncology, Oncology, Body Mass Index +7

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Begoña de las Heras, Kamal S. Saini, Frances Boyle et al. · Oncology and Therapy · 2020 · 31 citations · Full text